Phaseline

Targets › MIF

MIF (Macrophage migration inhibitory factor): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology, Other; next expected readout Jan 2027.

Pro-inflammatory cytokine involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. (UniProt, P14174)

Open in Phaseline: the race on MIF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nanjing Immunophage BiotechIPG1094
Macrophage migration inhibitory factor (MIF) inhibitor
MIFPhase 1Healthy Volunteers; Solid TumorJan 2027

Conditions

Healthy Volunteers (1) Solid Tumor (1)

Modalities

small molecule (1)

Companies

Nanjing Immunophage Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.